Corre na lista francesa "parkliste" a not�cia de um estudo apresentado no �ltimo encontro anual (127) da Associa�ao Americana de Neurologia (ANA) questionando a id�ia de que, a longo prazo, o uso continuado de levodopa pudesse acelerar a progress�o da DP ou a severidade dos sintomas. Nesse mesmo evento o dr Clifford Walter Shults, M.D., University of California San Diego, La Jolla, CA, apresentou um trabalho sobre os efeitos positivos da Coenzyme Q10, intitulado: "Effect of Coenzyme Q10 in early Parkinson�s Disease: Evidence for slowing of the
functional decline".
-----Mensagem Original-----
De: M.Schild
Enviado: domingo, 27 de outubro de 2002 03:04
Para: Parkliste
Assunto: Ldopa
Les craintes liees au traitement de longue duree a la Ldopa peuvent etre
oubliees. les effets neurotoxiques de la Ldopa in vitro, ne se retrouvent pas
in vivo sur des MP de longues duree (apres autopsie)
This is a press release from the American Neurological Association (ANA)
Meeting:
ANA: Concern About Long-Term Levodopa Use in Parkinson's Patients is
Unfounded
By Jill Stein
Special to DG News
NEW YORK, NY -- October 17, 2002 -- Concern about an increased rate of
disease progression or severity of symptoms resulting from long-term use of
levodopa in Parkinson's disease (PD) patients is not justified, researchers
said here October 15 at the 127th Annual Meeting of the American
Neurological Association (ANA).
Reports based on in vitro cell culture studies have raised the issue that
levodopa administration can produce irreversible toxic reactions to
dopaminergic neurons.
To clarify whether these toxic reactions also occur in humans treated with
levodopa, Dr. Melvin Yahr, from Mount Sinai School of Medicine, in New York,
New York, United States, reviewed the charts of 36 patients who had been
treated primarily with levodopa with or without carbidopa for at least 20
years and who received on occasion ancillary antiparkinsonian agents for a
limited period of time. The researchers studied the course of their disease,
the response to levodopa, the complications encountered and the functional
state, as well as survival.
In addition, the investigators evaluated the autopsies of 33 patients who
had been on levodopa for various periods of time. Their pathological changes
were compared with patients who had not received levodopa or other
dopaminergic agents.
On average, patients reached an advanced stage of their PD in 23 years.
Postmortem studies showed morphologic changes characteristic of PD -- nigral
cell loss and Lewy body formation. Surviving nigral neurons were present and
appeared normal.
Dr. Yahr said that the data do not support the in vitro findings that
levodopa is neurotoxic to dopaminergic neurons. He said that the present
study confirms that levodopa can be used safely in patients with PD.
Envoi de pieces-jointes : piece-jointe@parkliste.org
Site Parkliste : http://www.parkliste.org
Liste Partenaires (conjoints et proches)envoyer un message vide � :join-Partenaires@lyris.coles.org.uk
Sent to: [marciliosantos@hotmail.com]
Nenhum comentário:
Postar um comentário
Observamos que muitos comentários são postados e não exibidos. Certifique-se que seu comentário foi postado com a alteração da expressão "Nenhum comentário" no rodapé. Antes de reenviar faça um refresh. Se ainda não postado (alterado o n.o), use o quadro MENSAGENS da coluna da direita. Grato.